BiotechTube
Phaim Pharma

Phaim Pharma

London, United Kingdom· Est.
phaim.co.uk
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $1.5M

Overview

Phaim Pharma is a clinical-stage biotech pioneering Antigenic Immune Modulation (AIM), a platform designed to reset the immune system to cure or halt autoimmune diseases. Its lead program targets Type 1 Diabetes (T1D), a condition with significant unmet need and no current disease-modifying therapies. Backed by a leadership team with deep expertise in immunology and drug development, Phaim is positioning itself to address a large and growing autoimmune market. The company is privately held, pre-revenue, and has secured non-dilutive funding and awards to advance its research.

Autoimmune DiseasesType 1 DiabetesPsoriasisRheumatoid ArthritisMultiple Sclerosis

Technology Platform

Antigenic Immune Modulation (AIM) - a therapeutic platform designed to reset the immune system to cure, halt, or prevent autoimmune disease by modulating the immune response to specific autoantigens.

Funding History

1
Total raised:$1.5M
Seed$1.5M

Opportunities

The significant unmet need in Type 1 Diabetes, a condition with no cure and a growing global patient population, presents a massive market opportunity for a disease-modifying therapy.
Success with the lead T1D program would validate the AIM platform, enabling rapid expansion into other large autoimmune markets like psoriasis and RA, creating a pipeline of high-value assets.

Risk Factors

The primary risk is clinical failure of the novel AIM platform, which is unproven in late-stage trials for complex autoimmune diseases.
The company also faces financial risk as a pre-revenue biotech reliant on fundraising, and intense competition from larger firms developing similar immunomodulatory therapies.

Competitive Landscape

Phaim operates in the competitive field of antigen-specific immunotherapies for autoimmunity, facing rivals ranging from large pharma (e.g., Novo Nordisk, Sanofi) to biotechs (e.g., Provention Bio, now Sanofi). Its differentiation hinges on the specific mechanism and efficacy of its AIM platform. The T1D space, while crowded with insulin and device companies, has few late-stage curative candidates, leaving room for a breakthrough.

More companies in Immunotherapy / Immuno-Oncology →More companies in United Kingdom →